Amica Mutual Insurance Co. Has $4.63 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)


Share on StockTwits

Amica Mutual Insurance Co. lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 21.1% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 20,446 shares of the medical research company’s stock after selling 5,461 shares during the period. Amica Mutual Insurance Co.’s holdings in Charles River Laboratories International were worth $4,630,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. Carroll Financial Associates Inc. boosted its position in shares of Charles River Laboratories International by 1,628.6% during the 3rd quarter. Carroll Financial Associates Inc. now owns 121 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 114 shares in the last quarter. Altshuler Shaham Ltd acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at about $28,000. Trust Co. of Vermont acquired a new stake in shares of Charles River Laboratories International during the 3rd quarter valued at about $31,000. SeaBridge Investment Advisors LLC acquired a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $35,000. Finally, Front Row Advisors LLC boosted its position in shares of Charles River Laboratories International by 22.1% during the 2nd quarter. Front Row Advisors LLC now owns 260 shares of the medical research company’s stock valued at $45,000 after acquiring an additional 47 shares in the last quarter. 87.83% of the stock is owned by institutional investors.

Several analysts have recently weighed in on CRL shares. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Charles River Laboratories International from $235.00 to $250.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Truist boosted their price target on shares of Charles River Laboratories International from $237.00 to $256.00 in a research report on Tuesday, November 3rd. Citigroup boosted their price target on shares of Charles River Laboratories International from $190.00 to $255.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Zacks Investment Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $261.00 price target on the stock in a research report on Tuesday, November 3rd. Finally, Argus boosted their price target on shares of Charles River Laboratories International from $190.00 to $235.00 and gave the company a “buy” rating in a research report on Monday, September 14th. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $210.58.

Shares of CRL traded down $0.92 during trading hours on Friday, hitting $232.54. The company had a trading volume of 288,038 shares, compared to its average volume of 392,061. The firm has a market cap of $11.57 billion, a price-to-earnings ratio of 38.76, a PEG ratio of 2.16 and a beta of 1.18. The business has a fifty day moving average of $236.51 and a 200-day moving average of $204.07. Charles River Laboratories International, Inc. has a 12 month low of $95.58 and a 12 month high of $257.88. The company has a quick ratio of 1.22, a current ratio of 1.45 and a debt-to-equity ratio of 1.04.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, October 29th. The medical research company reported $2.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.53. Charles River Laboratories International had a net margin of 10.68% and a return on equity of 22.41%. The company had revenue of $743.30 million for the quarter, compared to analyst estimates of $715.63 million. During the same period in the prior year, the firm earned $1.69 earnings per share. The company’s revenue was up 11.3% on a year-over-year basis. On average, equities analysts expect that Charles River Laboratories International, Inc. will post 7.86 EPS for the current fiscal year.

In other news, Director George Massaro sold 1,943 shares of Charles River Laboratories International stock in a transaction on Monday, September 14th. The shares were sold at an average price of $219.91, for a total value of $427,285.13. Following the completion of the sale, the director now owns 11,384 shares in the company, valued at approximately $2,503,455.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP William D. Barbo sold 2,150 shares of Charles River Laboratories International stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $236.29, for a total transaction of $508,023.50. Following the completion of the sale, the vice president now owns 5,899 shares of the company’s stock, valued at approximately $1,393,874.71. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 32,832 shares of company stock worth $7,734,306. 1.90% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Story: The Role of a Fiduciary and Individual Investors

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.